Kevin Chiang

General Manager
Genomics BioSci & Tech Co., Ltd
​

Mr. Kevin Chiang, General Manager of Genomics BioSci & Tech, has nearly 20 years of experience in the genomics field. With a strong background spanning both the technical and commercial aspects of gene sequencing technologies, genomic services, and related products, he possesses a deep understanding of the critical role that genomic information and technologies play in life sciences and human health.
Mr. Chiang has leveraged his extensive expertise to lead Genomics from its foundation in gene sequencing into broader multi-omics platforms and, more recently, into the oligonucleotide and peptide CDMO space. His vision and leadership continue to drive the company’s expansion and innovation, positioning Genomics as an integrated solution provider across research, diagnostics, and precision medicine.
In 2017, I returned to the pharmaceutical industry, taking on strategic roles at OrientEuro Pharma and subsequently Orient Pharma, where I led market access planning for 505(b)(2) new drugs. I successfully secured Taiwan’s first-in-market NHI reimbursement pricing for CV/CNS product and developed real-world evidence (RWE) strategies to support post-launch lifecycle extension. By challenging the traditional mindset that defines drugs as either originator or generic, I helped pioneer the positioning and medical adoption of me-better therapies within the healthcare system, enabling the Orient Group to enter a new blue ocean of specialty biotech innovation.​

 

Speech title & Synopsis

Company Profile

Genomics BioSci & Tech is a next-generation biotechnology company based in Taiwan, specializing in advanced gene sequencing and CDMO (Contract Development and Manufacturing Organization) services for oligonucleotide- and peptide-based products. By integrating a comprehensive gene sequencing platform, bioinformatics and genomic data analysis, along with precise synthesis and manufacturing capabilities, Genomics delivers vertically integrated solutions for global clients in drug development, diagnostics, and precision medicine.
As a pioneer in sequencing technology in Taiwan, we offer high-throughput and customized sequencing services, including Sanger sequencing, whole genome sequencing (WGS), whole exome sequencing (WES), RNA-seq, targeted sequencing, and pathogen detection. We operate one of the most complete sequencing platforms in Taiwan, spanning Sanger, next-generation sequencing (NGS), and long-read sequencing technologies. These services are supported by advanced analytics for biomarker discovery, mutation profiling, and genomic database development.
In addition, our oligonucleotide synthesis services support production scales ranging from research-grade to clinical-grade, with capabilities for small-scale, diverse peptide synthesis optimized for neoantigen-based applications.
With strong R&D expertise, in-house manufacturing infrastructure, and a collaborative mindset, Genomics BioSci & Tech bridges genomics and synthesis, enabling partners to accelerate the journey from sequence to solution.